Affiliations: Department of Breast Surgery, Cancer Hospital/Cancer
Institute, Fudan University, Shanghai, 200032, P.R. China | Department of Medicine and Vanderbilt-Ingram Cancer
Center, Vanderbilt University School of Medicine, Nashville, TN 37232,
USA | Department of Radiation Oncology and Vanderbilt-Ingram
Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232,
USA
Note: [] Visiting research fellow at Vanderbilt University School of
Medicine, Nashville, TN 37232, USA
Note: [] Address for correspondence: Bo Lu, M.D., Ph.D., Department of
Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, TN 37232, USA. Fax.: +1 615 343 0161; E-mail:
Bo.Lu@vanderbilt.edu
Abstract: Endostatin is an important inhibitory molecule which mediates the
sequential steps involved in angiogenesis. Lower level or impaired function of
endostatin is associated with a higher risk of developing malignant solid
tumors and with a worse prognosis of the disease. The endostatin N104
polymorphism might be associated with an impaired ability to inhibit
angiogenesis. We analyzed the tissues from 98 Caucasian prostate cancer
patients for the presence of D104N polymorphism. The frequencies of homozygous
4349G/G(104D/D), and heterozygous 4349G/A(104D/N) were 83.67%(82/98) and
16.33%(16/98), respectively; no individuals were homozygous 4349A/A(104N/N).
With the Fisher's exact test we found the genotype of D104N was not
significantly related to age, tumor grade, PSA and clinical stage (P >
0.05). There was no difference in relapse free survival(RFS) or overall
survival(OS) between patients with 104D/N and those with 104D/D (P = 0.8283,
0.3713 respectively). We concluded that endostatin polymorphism was not
associated with the aggressiveness of prostate cancer in Caucasian
patients.
